BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/7/2021 11:17:20 AM | Browse: 551 | Download: 1048
 |
Received |
|
2021-01-29 21:50 |
|
Peer-Review Started |
|
2021-01-29 21:56 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-04-06 05:39 |
|
Revised |
|
2021-04-13 22:14 |
|
Second Decision |
|
2021-05-10 09:33 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-05-10 09:49 |
|
Articles in Press |
|
2021-05-10 09:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-06-03 00:36 |
|
Publish the Manuscript Online |
|
2021-06-07 11:17 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Harold W Davis, Ahmet Kaynak, Subrahmanya D Vallabhapurapu and Xiaoyang Qi |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Pancreatic Cancer Action Network Translational Research Grant |
20-65-QIXI |
| Give Hope Foundation, National Institutes of Health |
R01CA158372 |
| Give Hope Foundation, National Institutes of Health |
R21NS095047 |
| CCTST Pilot Collaborative Studies, Bearcats Against Cancer, and Hematology-Oncology Programmatic Support from University of Cincinnati College of Medicine |
|
|
| Corresponding Author |
Xiaoyang Qi, PhD, Professor, Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Brain Tumor Center at UC Neuroscience Institute, 3512 Eden Avenue, Cincinnati, OH 45267, United States. xiaoyang.qi@uc.edu |
| Key Words |
Pancreatic cancer; Saposin C; Dioleoylphosphatidylserine; Phosphatidylserine-targeted therapy; Chemotherapy; Radiation |
| Core Tip |
This review presents the mechanisms and efficacy of saposin C-dioleoylphosphatidylserine (SapC-DOPS), a novel phosphatidylserine (PS) biomarker-targeted nanodrug, alone and in combination with other treatment modalities for the treatment of pancreatic ductal adenocarcinoma (PDAC) tumors. Our results indicate that SapC-DOPS preferentially targets cells with high surface PS which are primarily in the G2/M phase of the cell cycle. Other treatment modalities such as Gemcitabine, Abraxane and radiation target G1 phase cells that have low surface PS. Combination of SapC-DOPS and Gemcitabine/Abraxane or radiation significantly inhibits tumor growth of orthotopic PDAC tumors in vivo and increases survival compared to individual treatments. |
| Publish Date |
2021-06-07 11:17 |
| Citation |
Davis HW, Kaynak A, Vallabhapurapu SD, Qi X. Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer. World J Gastrointest Oncol 2021; 13(6): 550-559 |
| URL |
https://www.wjgnet.com/1948-5204/full/v13/i6/550.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v13.i6.550 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
